{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:43:12Z","timestamp":1780638192995,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.tjog.2023.07.019","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T02:18:57Z","timestamp":1694139537000},"page":"745-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab"],"prefix":"10.1016","volume":"62","author":[{"given":"Kaoru","family":"Niimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2023.07.019_bib1","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.3802\/jgo.2022.33.e72","article-title":"Epidemiologic study on gestational trophoblastic diseases in Japan","volume":"33","author":"Yamamoto","year":"2022","journal-title":"Journal of gynecologic oncology"},{"key":"10.1016\/j.tjog.2023.07.019_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ygyno.2005.02.004","article-title":"Secondary chemotherapy for high-risk gestational trophoblastic neoplasia","volume":"97","author":"Lurain","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2023.07.019_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.bjc.6603608","article-title":"A\u00a0comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia","volume":"96","author":"Powles","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tjog.2023.07.019_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10147-019-01540-9","article-title":"The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia","volume":"25","author":"Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.tjog.2023.07.019_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2021.100819","article-title":"An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab","volume":"37","author":"Bell","year":"2021","journal-title":"Gynecologic oncology reports"},{"key":"10.1016\/j.tjog.2023.07.019_bib6","first-page":"94","volume":"vol. 121","author":"Choi","year":"2019"},{"key":"10.1016\/j.tjog.2023.07.019_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2020.100625","article-title":"Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors","volume":"34","author":"Clair","year":"2020","journal-title":"Gynecologic oncology reports"},{"key":"10.1016\/j.tjog.2023.07.019_bib8","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.tjog.2023.07.019_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2022.100955","article-title":"Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy","volume":"40","author":"Wong","year":"2022","journal-title":"Gynecologic oncology reports"},{"key":"10.1016\/j.tjog.2023.07.019_bib10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3892\/mco.2016.1011","article-title":"High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: a case report and literature review","volume":"5","author":"Yamamoto","year":"2016","journal-title":"Molecular and clinical oncology"},{"key":"10.1016\/j.tjog.2023.07.019_bib11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","article-title":"Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors","volume":"40","author":"Inaguma","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.tjog.2023.07.019_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2019.08.006","article-title":"Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer","volume":"155","author":"Liu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2023.07.019_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2023.07.019_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2023.07.019_bib15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2023.07.019_bib16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2023.07.019_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1016\/j.tjog.2024.04.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455923001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455923001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T20:47:02Z","timestamp":1699476422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455923001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1028455923001924"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2023.07.019","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.tjog.2024.04.003","asserted-by":"object"}]},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2023.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}